Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesImmunology/RheumatologyCommunity-Care Benlysta IV Coverage Prior Auth | O…
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Benlysta IV (belimumab) Medical Benefit Medication Utilization Policy

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical benefit coverage criteria, authorization, and coding for intravenous belimumab (Benlysta) for systemic lupus erythematosus and active lupus nephritis for Community-Care members and providers.

    Policy Summary
    PayerCommunity-Care
    PolicyBenlysta IV (belimumab) Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJun 1, 2024
    Next Review DateJun 1, 2024
    Key ActionObtain prior authorization with documentation of specialty prescriber, diagnosis, supporting serologies, prior therapy failures or intolerance, and patient weight.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsinitial authorization period
    1 yearcontinuation authorization period
    J0490HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=7.5 mg
    corticosteroid threshold

    Coverage criteria for belimumab (Benlysta)

    Initial Therapy - Systemic lupus erythematosus

    Covered when ALL of the following are met:

    SLE initial criteria

    • Serology: Documentation of one of: anti-dsDNA positive; low complement C3 or C4; or anti-Smith antibodies
    • Prior therapies: Two of the following are ineffective, contraindicated, or not tolerated: hydroxychloroquine; methotrexate; azathioprine; mycophenolate mofetil; chronic corticosteroid treatment at >= 7.5 mg prednisone daily or equivalent2 of 5
    • Exclusions: Does not have severe active CNS lupus; will not be given in combination with other biologics

    Initial Therapy - Active lupus nephritis

    Covered when ALL of the following are met:

    Lupus nephritis initial criteria: Diagnosis of active lupus nephritis in a patient receiving standard therapy

    Prescriber must be or consult with a rheumatologist or nephrologist

    Exclusions: Does not have severe active CNS lupus; will not be given in combination with other biologics or with voclosporin

    Continuation Therapy

    Covered when ALL of the following are met:

    Continuation criteria: Prescribed by, or in consultation with, an appropriate specialist; diagnosis of active, autoantibody-positive SLE or active lupus nephritis; documentation of disease stabilization or improvement on belimumab

    Must not have severe active CNS lupus; not given with other biologics; if for lupus nephritis, not given with voclosporin

    The policy expressly excludes patients with severe active central nervous system (CNS) lupus from coverage for belimumab (Benlysta). Requests for belimumab will also be denied when it is to be administered in combination with other biologic therapies. For the indication of active lupus nephritis, the policy additionally prohibits combination use with voclosporin.

    When assessing eligibility, confirm the absence of severe active CNS lupus because its presence is an exclusion for both initial and continuation approvals. Document that belimumab will not be co-administered with any other biologic agent; for patients treated for active lupus nephritis, also document that belimumab will not be used concomitantly with voclosporin. These combination-therapy restrictions apply at both initiation and renewal.

    Billing and coding

    Applicable HCPCS CodesHCPCSCovered
    J0490Injection, belimumab, 10 mg
    Chronic corticosteroid threshold — prednisone-equivalent
    Threshold (prednisone-equivalent)>= 7.5 mg prednisone daily (or equivalent)
    Context where usedCounts as one of the required two prior therapies for initial SLE approval when chronic corticosteroid treatment meets threshold
    Policy locationListed under Initial Approval — Systemic lupus erythematosus, item iv.5

    Prior authorization, required documentation, and denial conditions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Benlysta IV. Requests must document the specialty prescriber, diagnosis, supporting serologies, prior therapy history, and intended treatment plan.

    • Prescriber: rheumatologist, nephrologist, or dermatologist (as appropriate to indication).
    • Diagnosis: active, autoantibody-positive systemic lupus erythematosus OR active lupus nephritis.
    • Supporting serologies: anti-dsDNA positive, low complement (C3 or C4), or anti-Smith antibodies.
    Step Therapy

    Step therapy (Required Prior Therapies)

    For systemic lupus erythematosus (SLE) prior to approval, the medical record must show that at least two of the listed standard therapies are ineffective, contraindicated, or not tolerated.

    • Required trial history must include TWO of the following: hydroxychloroquine; methotrexate; azathioprine; mycophenolate mofetil; chronic corticosteroid therapy ≥ 7.5 mg prednisone daily (or equivalent).

    Background

    Belimumab (Benlysta) is an intravenous biologic indicated as adjunctive therapy for active, autoantibody-positive systemic lupus erythematosus and for active lupus nephritis. The policy requires that treatment be prescribed by—or in consultation with—an appropriate specialist (rheumatologist, dermatologist, or nephrologist as applicable) and that serologic evidence of disease activity (for example, anti-dsDNA positivity or low complement C3/C4) or clinical response be documented for initiation and continuation decisions.

    Key definitions

    Active, autoantibody-positive systemic lupus erythematosus — required laboratory evidence and clinical context
    DefinitionSystemic lupus erythematosus with laboratory evidence of autoantibodies in a patient receiving standard therapy
    Acceptable serologic evidenceOne of: anti-double stranded DNA (anti-dsDNA) positive; low complement (C3 or C4); or positive anti-Smith antibodies
    Prescriber requirementPrescribed by, or in consultation with, a rheumatologist or dermatologist (for SLE)
    Exclusion relevant to definitionPatient must not have severe active central nervous system (CNS) lupus
    Policy Summary
    PayerCommunity-Care
    PolicyBenlysta IV (belimumab) Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJun 1, 2024
    Next Review DateJun 1, 2024
    Key ActionObtain prior authorization with documentation of specialty prescriber, diagnosis, supporting serologies, prior therapy failures or intolerance, and patient weight.
    SourceLink
    On This Page
    Coverage criteria for belimumab (Benlysta)Billing and codingPrior authorization, required documentation, and denial conditionsBackgroundKey definitions
  1. Specify whether each listed therapy was ineffective, not tolerated, or contraindicated and include treatment dates/durations when available.
    2. Documentation Required

    Required Documentation

    Include the following documentation with the prior authorization request to avoid processing delays.

    • Specialty prescriber name and specialty (rheumatologist, nephrologist, or dermatologist).
    • Confirmed diagnosis with indication (active, autoantibody-positive SLE or active lupus nephritis).
    • Relevant serologies: anti-dsDNA, C3 and C4 complement levels, anti-Smith antibodies.
    • Detailed prior therapy history: medications tried, dates, reason for discontinuation (ineffective, intolerant, or contraindicated).
    • Weight (required for dosing and approval).
    • For continuation requests: documentation of disease stabilization or improvement on belimumab.
    Denial Risk

    Conditions That Trigger Denial

    Requests will be denied when contraindications or exclusion conditions are present.

    • Severe active central nervous system (CNS) lupus.
    • Request for concomitant use with other biologic therapies.
    • For lupus nephritis: concomitant use with voclosporin.
    • Insufficient documentation of required prior therapies or missing supporting serologies.
    • Lack of specialty prescriber or missing required weight information.